Last reviewed · How we verify
L-Dipalmitoyl Lecithin (COLFOSCERIL PALMITATE)
L-Dipalmitoyl Lecithin (generic name: COLFOSCERIL PALMITATE) is a colfosceril palmitate Small molecule drug developed by GSK. It is currently FDA-approved (first approved 1990) for Respiratory distress syndrome in the newborn.
L-Dipalmitoyl Lecithin is a small molecule with a mechanism of action as a lung surfactant. It is also known by various synonyms, including Colfosceryl Palmitate.
At a glance
| Generic name | COLFOSCERIL PALMITATE |
|---|---|
| Sponsor | GSK |
| Drug class | colfosceril palmitate |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1990 |
Approved indications
- Respiratory distress syndrome in the newborn
Common side effects
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Dipalmitoyl Lecithin CI brief — competitive landscape report
- L-Dipalmitoyl Lecithin updates RSS · CI watch RSS
- GSK portfolio CI
Frequently asked questions about L-Dipalmitoyl Lecithin
What is L-Dipalmitoyl Lecithin?
What is L-Dipalmitoyl Lecithin used for?
Who makes L-Dipalmitoyl Lecithin?
What is the generic name of L-Dipalmitoyl Lecithin?
What drug class is L-Dipalmitoyl Lecithin in?
When was L-Dipalmitoyl Lecithin approved?
What development phase is L-Dipalmitoyl Lecithin in?
Related
- Drug class: All colfosceril palmitate drugs
- Manufacturer: GSK — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Respiratory distress syndrome in the newborn
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing